胡斌,冯江龙,沈丹丹,邓超男,文静
HU Bin,FENG Jianglong,SHEN DANDan,DENG Chaonan,WEN Jing

• 1:贵州医科大学附属医院病理科
• 2:贵州医科大学附属医院超声中心

摘要(Abstract)：

目的:研究BRAF~(V600E)基因突变与甲状腺乳头状癌(PTC)的临床病理特征的相关性。方法:325例病理诊断为PTC患者作为PTC组,同期50例甲状腺良性病变患者作为对照组,取2组患者手术切除的病灶组织标本提取DNA,采用实时荧光定量PCR法检测2组标本BRAF~(V600E)突变情况,分析BRAF~(V600E)基因突变与PTC组患者临床病理特征的相关性。结果:PTC组患者BRAF~(V600E)基因突变率明显高于对照组,差异有高度统计学意义(P <0.001); PTC组患者BRAF~(V600E)基因突变与甲状腺被膜外侵犯、淋巴结转移及伴有桥本氏甲状腺炎的差异均有统计学意义(P <0.05),BRAF~(V600E)突变与PTC患者预后相关。结论:BRAF~(V600E)基因突变与PTC甲状腺被膜侵犯、淋巴结转移及桥本氏甲状腺炎相关,可作为PTC患者预后的判断依据。
Objective: To investigate the correlation between BRAF~(V600E) gene mutations and clinicopathological features of papillary thyroid carcinoma( PTC). Methods: 325 patients with PTC were collected as PTC group,while 50 patients with benign thyroid lesions as the control group. the focus paraffin tissues of both groups were taken as the specimen,and the DNA in the extracted samples were detected by real-time fluorescence quantitative polymerase chain reaction( PCR) to detect BRAF~(V600E) mutations in the 2 groups and to analyze the correlation between BRAF~(V600E) gene mutations and the clinicopathological features of PTC group. Results: The BRAF~(V600E) gene mutation rate in PTC group was significantly higher than that in the control group( P < 0. 001),and the difference between BRAF~(V600E) gene mutation and extra-membrane invasion, lymph node metastasis and Hashimoto 's thyroiditis in PTC group was statistically significant( P < 0. 05). Conclusion: BRAF~(V600E) gene mutation is associated with thyroid invasion,lymph node metastasis and Hashimoto's thyroiditis,and can be used as a basis for the prognosis of PTC.

关键词(KeyWords)： 预后;甲状腺乳头状癌;BRAF~(V600E)基因;淋巴结转移;被膜外侵犯;桥本甲状腺炎
prognosis;papillary thyroid carcinoma(PTC);BRAF~(V600E) gene;lymph node metastasis;extra-membrane invasion;hashimoto's thyroiditis

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81760141);; 贵州省自然科学基金资助项目[黔科合基础(2016)1122]

作者(Author): 胡斌,冯江龙,沈丹丹,邓超男,文静
HU Bin,FENG Jianglong,SHEN DANDan,DENG Chaonan,WEN Jing

DOI: 10.19367/j.cnki.2096-8388.2020.08.011

参考文献(References)：

• [1]丛舒，方利文，包鹤龄，等．1990年与2013年中国人群甲状腺癌疾病负担分析[J]．中华流行病学杂志，2016,37(6):773-777．
• [2]LIN P,HE R Q,HUANG Z G,et al.Role of global aberrant alternative splic-ingeventsin papillary thyroid cancer prognosis[J].Aging (Albany NY),2019,11 (7):2082-2097．
• [3]NASIRDEN A,SAITO T,FUKUMUR Y,et al.In Japanese patients with papillary thyroid carcinoma,,tert promoter mutation is associated with poor prognosis,in contrast to braf (v600e) mutation[J].Virchows Archiv,2016,469(6):687-696．
• [4]KIM W W,HA T K,BAE S K.Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis[J].J Otolaryngology Head Neck Surg,2018,47(1):4-9．
• [5]REN HSHEN Y,HU D,et al.Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tu-mor aggressiveness,but not with lymph mode metastasis[J].Cancer Management and Research,2018(10):1005-1013．
• [6]罗春华，林云，贺峥，等．甲状腺乳头状癌BRAFV600E及TERT启动子突变的预后意义[J]．中国医药指南，2018,16(32):7-9．
• [7]李飞波，陈赢，王建彪．BRAF~(T1799A)基因和TERT启动子突变在甲状腺乳头状癌诊治中的价值[J]．浙江医学，2018,40(10):1142-1146．
• [8]SZYMONEK M,KOWALIK A,KOPCZYNSKI J,et al.Immunohisto-chemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma[J].Oncotarget,2017,8(43):74897-74909．
• [9]LEE S E,HWANG T S,CHOI Y L,et al.Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAF thyroid[J].Thyroid,2017,27 (6):802-810．
• [10]CHEN D,Q I W,ZHANG P,et al.Investigation of BRAFV600E detection approaches in papillary thyroid carcinoma[J].Pathology Research and Pract,2018,214(2):303-307．
• [11]KIM J K,SEONG C Y,BAE I E,et al.Comparison of immunohistochemistry and direct sequencing methods for identification of the BRAF V600E mutation in papillary thyroid carcinoma[J].Ann Surg Oncology,2018,25(6):1775-1781．
• [12]MOON S,SONG Y S,KIM Y A,et al.Effects of coexistent BRAFV600Eand TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer:Ameta-analysis[J].Thyroid,2017,27(5):651-660．
• [13]PONGSAPICH W,CHONGKOLWATANA C,POUNGVA-RIN N,et al.BRAF mutation in cytologically indeterminate thyroid nodules:after reclassification of a variant thyroid carcinoma[J].Onco Targets Therapy,2019,12:1465-1473．
• [14]HUANG Y,DONG W,LI J,et al.Differential expression patterns and clinical significance of estrogen receptorαandβin papillary thyroid carcinoma[J].BMC Cancer,2014,14:383．
• [15]SUN J,ZHANG J,LU J,et al.BRAFV600Eand TERT promoter mutations in papillary thyroid carcinoma in Chinese patients[J].Plos One,2016,11(4):e0153319．
• [16]秦东广，李建民，高太虎，等．BRAFV600E突变与经典型甲状腺乳头状癌患者临床病理特征的相关性[J]．肿瘤研究与临床，2016,28(5):338-340．
• [17]洪玉蓉，罗志艳，闻卿．甲状腺结节细针穿刺标本BRAFV600E基因突变检测的临床应用[J]．中华超声影像学杂志，2015,24(8):671-674．
• [18]赵跃，吴冰杰，王朵朵，等．基于TCGA数据库分析BRAFV600E和RAS基因突变与甲状腺乳头状癌临床病理特征的相关性[J]．海南医学院学报，2019,25(1):1-4．
• [19]JIN L,CHEN E,DONG S,et al.BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma:a study of 653 patients[J].Oncotarget,2016,7(14):18346-18355．
• [20]师艺，刘铭，马志萍，等．新疆地区甲状腺乳头状癌中BRAFV600E基因的表达及意义[J]．临床与实验病理学杂志，2016,32(8):887-890．
• [21]JEONG D,JEONG Y,PARK J H,et al.BRAF(V600E)mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR[J].Ann Surg Oncology,2013,20(3):759-766．
• [22]GOUVEIA C,CAN N T,BOSTROM A,et al.Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma:the University of California,San Francisco,experience[J].JAMA Otolaryngology Head Neck Surg,2013,139(11):1164-1170．
• [23]YU L,MA L,TU Q,et al.Clinical significance of BRAFV600Emutation in 154 patients with thyroid nodules[J].Oncology Letter,2015,9(6):2633-2638．
• [24]李英凤，王树军，郁敏，等．BRAFV600E基因蛋白在甲状腺乳头状癌中的表达及潜在的诊断价值[J]．诊断病理学杂志，2017,24(12):913-917．
• [25]谢楚平．BRAF基因突变与甲状腺乳头状癌淋巴结转移的相关性研究[J]．中国现代药物应用，2018,12(16):36-38．
• [26]巩雷，陈萍，刘宪军，等．甲状腺乳头状癌中D2-40、EG-FR和VEGF的表达及BRAF基因突变[J]．实用肿瘤杂志，2017,32(3):234-239．
• [27]王维娜，曹燕珍，陈海霞，等．甲状腺乳头状癌BRAFV600E基因突变与临床病理特征相关性研究[J]．新疆医科大学学报，2018,41(1):79-82,86．
• [28]KIM S J,MYONG J P,JEE H G.et al.Combined effect of Hashimoto's thyroiditis and BRAFV600Emutation status on ggressiveness in papillary thyroid cancer[J].Head Neck,2016,38(1):95-101．
• [29]ZENG R C,JIN L P,CHEN E D,et al.Potential relationship between Hashimoto's thyroiditis and BRAFV600Emutation status in papillary thyroid cancer[J].Head Neck,2016,38(Suppl 1):1019-1025.

文章评论(Comment)：